AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $17,403,000 | -71.4% | 785,000 | -62.4% | 1.47% | -46.1% |
| Q1 2022 | $60,840,000 | -11.4% | 2,090,000 | 0.0% | 2.73% | +40.9% |
| Q4 2021 | $68,698,000 | -31.2% | 2,090,000 | -3.5% | 1.94% | -22.2% |
| Q3 2021 | $99,915,000 | -16.3% | 2,165,000 | 0.0% | 2.49% | -17.9% |
| Q2 2021 | $119,313,000 | +6.7% | 2,165,000 | 0.0% | 3.03% | -9.0% |
| Q1 2021 | $111,801,000 | +8.6% | 2,165,000 | -8.8% | 3.33% | +9.2% |
| Q4 2020 | $102,909,000 | +68.0% | 2,375,000 | +35.7% | 3.05% | +11.2% |
| Q3 2020 | $61,250,000 | +7.0% | 1,750,000 | +63.6% | 2.74% | -19.0% |
| Q2 2020 | $57,224,000 | +50.7% | 1,070,000 | 0.0% | 3.39% | -16.0% |
| Q1 2020 | $37,964,000 | -3.6% | 1,070,000 | +29.7% | 4.03% | +11.2% |
| Q4 2019 | $39,394,000 | -99.9% | 825,000 | -11.8% | 3.62% | +15.6% |
| Q3 2019 | $30,294,000,000 | +22.7% | 935,000 | +88.9% | 3.14% | +35.7% |
| Q2 2019 | $24,690,600,000 | +109189.1% | 495,000 | +47.8% | 2.31% | -6.9% |
| Q1 2019 | $22,592,000 | +10.1% | 335,000 | -24.7% | 2.48% | -29.3% |
| Q4 2018 | $20,519,000 | -54.1% | 445,000 | -23.2% | 3.51% | -35.4% |
| Q3 2018 | $44,712,000 | +45.5% | 579,776 | +58.9% | 5.43% | +26.5% |
| Q2 2018 | $30,725,000 | +3.0% | 364,776 | 0.0% | 4.30% | -18.1% |
| Q1 2018 | $29,831,000 | +63.1% | 364,776 | +14.0% | 5.25% | +17.8% |
| Q4 2017 | $18,294,000 | +7.5% | 320,000 | +25.5% | 4.46% | -7.3% |
| Q3 2017 | $17,021,000 | +29.7% | 255,000 | 0.0% | 4.81% | -1.0% |
| Q2 2017 | $13,120,000 | -5.4% | 255,000 | +7.4% | 4.85% | -40.7% |
| Q1 2017 | $13,870,000 | +38.2% | 237,500 | -1.2% | 8.18% | -1.3% |
| Q4 2016 | $10,036,000 | -32.7% | 240,500 | -14.9% | 8.29% | -31.4% |
| Q3 2016 | $14,919,000 | +89.9% | 282,443 | +50.6% | 12.08% | +54.5% |
| Q2 2016 | $7,855,000 | +30.7% | 187,500 | +26.7% | 7.82% | +13.4% |
| Q1 2016 | $6,009,000 | -8.8% | 148,000 | +45.8% | 6.90% | +18.5% |
| Q4 2015 | $6,590,000 | – | 101,500 | – | 5.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |